Priorities far beyond generating morbidity or mortality data are needed to improve patients’ experiences, innovate metrics, and advance surgical palliation as a field.
AMA J Ethics. 2021; 23(10):E806-810. doi:
10.1001/amajethics.2021.806.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020; 22(8):E743-750. doi:
10.1001/amajethics.2020.743.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020; 22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020; 22(3):E221-231. doi:
10.1001/amajethics.2020.221.